MA52123A - Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2 - Google Patents

Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2

Info

Publication number
MA52123A
MA52123A MA052123A MA52123A MA52123A MA 52123 A MA52123 A MA 52123A MA 052123 A MA052123 A MA 052123A MA 52123 A MA52123 A MA 52123A MA 52123 A MA52123 A MA 52123A
Authority
MA
Morocco
Prior art keywords
erk1
pyrimidine
inhibitor
derivative used
isoindole derivative
Prior art date
Application number
MA052123A
Other languages
English (en)
Inventor
Bozena Ewa Adamczyk
Paul Anthony Baguley
Colin Thomas Lindley
Robert Craig Melling
Michael Reader
Mark Henry Saunders
Mirka Scarati
Nicola Elizabeth Wilsher
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MA52123A publication Critical patent/MA52123A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MA052123A 2017-04-20 2018-04-20 Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2 MA52123A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1706327.2A GB201706327D0 (en) 2017-04-20 2017-04-20 A pharmaceutical compound

Publications (1)

Publication Number Publication Date
MA52123A true MA52123A (fr) 2020-02-26

Family

ID=58795788

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052123A MA52123A (fr) 2017-04-20 2018-04-20 Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2

Country Status (18)

Country Link
US (1) US11142518B2 (fr)
EP (1) EP3612524A1 (fr)
JP (1) JP7113846B2 (fr)
KR (1) KR102652193B1 (fr)
CN (1) CN110831939A (fr)
AU (1) AU2018255935B2 (fr)
BR (1) BR112019019948A2 (fr)
CA (1) CA3059674A1 (fr)
GB (1) GB201706327D0 (fr)
IL (1) IL269803B (fr)
MA (1) MA52123A (fr)
MX (1) MX2019012471A (fr)
PH (1) PH12019502154A1 (fr)
SA (1) SA519410253B1 (fr)
SG (1) SG11201909189QA (fr)
TW (1) TWI813566B (fr)
WO (1) WO2018193410A1 (fr)
ZA (1) ZA201907484B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47013A (fr) 2015-10-21 2018-08-29 Otsuka Pharma Co Ltd Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
JP7326305B2 (ja) 2018-03-02 2023-08-15 大塚製薬株式会社 医薬化合物
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
WO2021149817A1 (fr) * 2020-01-24 2021-07-29 Taiho Pharmaceutical Co., Ltd. Amélioration de l'activité anti-tumorale de la pyrimidinone inhibitrice de shp2 en association avec de nouveaux médicaments anti-cancéreux contre le cancer
IL297743B2 (en) * 2020-04-30 2024-06-01 Medshine Discovery Inc Compounds containing benzosulatum
CN113967198A (zh) * 2020-07-24 2022-01-25 鲁南制药集团股份有限公司 一种甾体cyp17抑制剂胶囊及其制备方法
CA3190001A1 (fr) * 2020-08-21 2022-02-24 Shanghai Ringene Biopharma Co., Ltd. Compose lactame a cyclique aromatique, son procede de preparation et son utilisation
WO2022259222A1 (fr) 2021-06-11 2022-12-15 Otsuka Pharmaceutical Co., Ltd. Procédé de préparation d'un inhibiteur d'erk
US11931370B2 (en) * 2021-10-08 2024-03-19 Slayback Pharma Llc Stable pharmaceutical compositions of cyclophosphamide
AU2022376165A1 (en) 2021-10-26 2024-05-16 Otsuka Pharmaceutical Co., Ltd. Compositions comprising an erk inhibitor
CN114085213B (zh) * 2022-01-20 2022-03-25 苏州国匡医药科技有限公司 一种arv-471的制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5958934A (en) 1996-05-23 1999-09-28 Syntex (U.S.A.) Inc. Aryl pyrimidine derivatives and uses thereof
CA2333927A1 (fr) 1998-04-01 1999-10-07 Dupont Pharmaceuticals Company Antagonistes de l'integrine
JP2005500294A (ja) 2001-06-19 2005-01-06 ブリストル−マイヤーズ スクイブ カンパニー ホスホジエステラーゼ7に対するピリミジン阻害剤
CA2524221A1 (fr) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Heteroaryles substitues utilises en tant qu'inhibiteurs des proteine-tyrosine phosphatases
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
JP5010917B2 (ja) 2003-08-29 2012-08-29 エグゼリクシス, インコーポレイテッド c−Kit調節因子および使用方法
ES2897422T3 (es) 2004-05-14 2022-03-01 Vertex Pharma Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos
US20060235036A1 (en) 2005-04-15 2006-10-19 Doherty Elizabeth M Vanilloid receptor ligands and their use in treatments
WO2007070398A1 (fr) 2005-12-13 2007-06-21 Schering Corporation Derives polycycliques d'indazole inhibiteurs des erk
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US8258129B2 (en) 2006-07-06 2012-09-04 Boehringer Ingelheim International Gmbh 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
WO2008008059A1 (fr) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Agents anti-cancer et leurs utilisations
WO2008124085A2 (fr) 2007-04-03 2008-10-16 Exelixis, Inc. Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2
WO2009017838A2 (fr) 2007-08-01 2009-02-05 Exelixis, Inc. Combinaisons d'inhibiteurs jak-2 et d'autres agents
WO2009039635A1 (fr) 2007-09-24 2009-04-02 Painceptor Pharma Corporation Procédés de modulation d'une activité médiée par la neurotrophine
CA2700841A1 (fr) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Composes d'isoindoline pour le traitement d'une amyotrophie spinale et autres utilisations
PT2231640E (pt) 2008-01-24 2012-08-23 Merck Patent Gmbh Derivados beta-aminoácido para o tratamento de diabetes
CA2986640C (fr) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Composes hetero-aryles et leurs utilisations
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
US8084620B2 (en) 2008-12-19 2011-12-27 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
US8716326B2 (en) 2009-05-15 2014-05-06 Korea Research Institute Of Chemical Technology Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same
WO2010151747A1 (fr) 2009-06-26 2010-12-29 Cystic Fibrosis Foundation Therapeutics, Inc. Composés de pyramine ainsi que leurs procédés de fabrication et d'utilisation
WO2011008931A2 (fr) 2009-07-15 2011-01-20 Cystic Fibrosis Foundation Therapeutics, Inc. Composés arylpyrimidines et thérapie de combinaison comprenant ceux-ci pour traiter une mucoviscidose et des troubles apparentés
SG10201502073PA (en) 2009-12-22 2015-05-28 Vertex Pharma Isoindolinone inhibitors of phosphatidylinositol 3-kinase
EP2515903A4 (fr) 2009-12-23 2013-07-10 Peter Maccallum Cancer Inst Composés, leurs préparations et leurs utilisations
RU2012132682A (ru) 2009-12-31 2014-02-10 Пирамал Энтерпрайзис Лимитед Ингибиторы диацилглицерин ацилтрансферазы
CN102985405B (zh) 2010-07-02 2016-07-06 Aska制药株式会社 杂环化合物及p27Kip1分解抑制剂
EA025611B1 (ru) 2010-07-29 2017-01-30 Райджел Фармасьютикалз, Инк. Активирующие ampk гетероциклические соединения и способы их использования
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
RU2650501C2 (ru) 2012-03-01 2018-04-16 Эррэй Биофарма Инк. Ингибиторы серин/треониновых киназ
WO2014040555A1 (fr) 2012-09-12 2014-03-20 山东亨利医药科技有限责任公司 Dérivé de noyau hétéroaromatique contenant de l'azote utile comme inhibiteur de la tyrosine kinase
US20150272939A1 (en) 2012-10-02 2015-10-01 Yale University Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase
RS58023B2 (sr) 2012-11-01 2021-12-31 Infinity Pharmaceuticals Inc Lečenje kancera korišćenjem modulatora izoformi pi3 kinaza
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
WO2014130856A2 (fr) 2013-02-21 2014-08-28 Wayne Rothbaum Traitement de troubles associés au squelette
TWI692477B (zh) 2013-08-30 2020-05-01 美商Ptc治療公司 經取代嘧啶bmi-1抑制劑
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
GEP20196983B (en) * 2014-01-14 2019-06-25 Millennium Pharm Inc Heteroaryls and uses thereof
KR20170003553A (ko) 2014-04-04 2017-01-09 사이로스 파마수티컬스, 인크. 사이클린-의존성 키나제 7(cdk7)의 저해제
WO2015157556A1 (fr) 2014-04-09 2015-10-15 Kadmon Corporation, Llc Traitement de la réaction du greffon contre l'hôte
WO2016025649A1 (fr) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinaisons d'un inhibiteur d'erk et d'un inhibiteur de dot1l et procédés associés
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
WO2016162325A1 (fr) 2015-04-07 2016-10-13 Astrazeneca Ab Dérivés de 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-ones substitués utilisés comme inhibiteurs de kinase
RU2017139727A (ru) * 2015-06-15 2019-07-16 АСАНА БАЙОСАЙЕНСИЗ, ЭлЭлСи Гетероциклические ингибиторы erk1 и erk2 и их применение для лечения злокачественного новообразования
MA47013A (fr) * 2015-10-21 2018-08-29 Otsuka Pharma Co Ltd Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
DK3374359T3 (da) 2015-11-09 2020-03-30 Astrazeneca Ab Dihydroimidazopyrazinonderivater, der er nyttige ved behandling af cancer
WO2018019204A1 (fr) 2016-07-26 2018-02-01 深圳市塔吉瑞生物医药有限公司 Composé amino pyrimidine pour inhiber l'activité de la protéine tyrosine kinase

Also Published As

Publication number Publication date
KR102652193B1 (ko) 2024-03-29
MX2019012471A (es) 2019-12-11
EP3612524A1 (fr) 2020-02-26
US11142518B2 (en) 2021-10-12
SG11201909189QA (en) 2019-10-30
WO2018193410A1 (fr) 2018-10-25
BR112019019948A2 (pt) 2020-04-28
ZA201907484B (en) 2024-05-30
RU2019135029A (ru) 2021-05-20
KR20190140957A (ko) 2019-12-20
GB201706327D0 (en) 2017-06-07
PH12019502154A1 (en) 2020-06-29
TW201842912A (zh) 2018-12-16
IL269803B (en) 2022-09-01
CA3059674A1 (fr) 2018-10-25
TWI813566B (zh) 2023-09-01
CN110831939A (zh) 2020-02-21
RU2019135029A3 (fr) 2021-07-16
IL269803A (en) 2019-11-28
US20210101889A1 (en) 2021-04-08
JP7113846B2 (ja) 2022-08-05
AU2018255935B2 (en) 2022-03-17
JP2020517598A (ja) 2020-06-18
AU2018255935A1 (en) 2019-11-07
US20220169638A1 (en) 2022-06-02
SA519410253B1 (ar) 2023-07-12

Similar Documents

Publication Publication Date Title
MA52123A (fr) Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2
MA54547A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA54546A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA44725A (fr) Formulations d'un inhibiteur de lsd1
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA45189A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA43862A (fr) Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA42032A (fr) Acides 3-aryl-4-amido-bicyclo [4,5,0]hydroxamiques en tant qu'inhibiteurs de hdac
MA53352A (fr) Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
MA40775A (fr) Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
MA52063A (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp